This event has ended
Connecting Tomorrow’s Entrepreneurs with Today’s Leaders This event is part of a series of events that Propel Careers will be organizing in 2010 to increase connections between students and life sciences companies. Individual panels will be held to focus on different areas of life sciences including: therapeutics, medical device, diagnostics, healthcare IT. The goal of these events is to increase awareness for the many career paths which exist in this dynamic field. Together, we can harness passion and cultivate the next generation of life sciences leaders !

Career Paths in Therapeutic Life Sciences Companies

Propel Careers and MassDevice

Wednesday, January 27, 2010 from 5:30 PM to 8:00 PM (EST)

Boston, United States

Career Paths in Therapeutic Life Sciences Companies

Ticket Information

Ticket Type Sales End Price Fee Quantity
Student Ended $20.00 $0.00
Post-Doctoral Fellow Ended $20.00 $0.00
Other Ended $40.00 $0.00

Share Career Paths in Therapeutic Life Sciences Companies

Event Details

The panel will include speakers from the following companies:

 

Mirza Cifric Corporate Development, FORMA Therapeutics

Leslie Williams, Co-Founder and CEO, Amplicea Therapeutics

Hampus Hillerstrom, Co-CEO of NeuroPhage Pharmaceuticals

Christine Brennan, Exec Director of Strategic Alliances and Head of Strategy and Operations, Novartis

 

 

This panel will feature life sciences leaders from Boston area companies involved in the development of therapeutics for the treatment of human diseases.  The panelists will share their experiences and insights into their career paths, lessons learned, and emerging industry trends for students to consider as they contemplate their future careers.     

Join us for a night of networking among companies and fellow students to build your connections in the life sciences industry.  Refreshments and light fare will be provided.  

Time:  5:30pm – 8:00pm

(Registration starts at 5:30pm, panel starts as 6:15pm)

 

If you are a MA-based student interested in attending this event, financial assistance is available through the Stay in MA program.  Please visit www.stayinma.com.

Propel Careers Therapeutic Panel Speakers Biographies

Hampus Hillerstrom, Co-CEO, NeuroPhage Pharmaceuticals

Hampus is Co-CEO of NeuroPhage Pharmaceuticals, Inc.  Hampus co-founded NeuroPhage in 2006 during the 3rd semester of business school, where the project started as a field study evaluating the potential of an innovative drug and imaging technology platform for neurodegenerative diseases.  NeuroPhage’s lead drug candidate targets Alzheimer’s Disease and the company has raised $11M to date from private investors. Hampus graduated from the University of St.Gallen with a Masters in Economics and Finance.  Prior to graduating from HBS in 2007 and from the HST-BEP Program in 2008, Hampus interned a summer in Global Marketing at AstraZeneca. Prior to business school, he was an associate at a  $1B biotech venture capital firm HealthCap, partner at biotech-focused consulting boutique Venture Valuation and analyst in Lazard’s M&A department. Hampus is a Former Member of the HBS Healthcare Club Advisory Board. 

NeuroPhage Pharmaceuticals, Inc.

NeuroPhage is advancing a disease-modifying phage-based approach targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases.  NeuroPhage was founded in 2006 by Professor Beka Solomon, a leading neuroscience researcher from Tel Aviv University and pioneer of immunotherapy for Alzheimer’s, together with a Cambridge-based entrepreneurial team.  NeuroPhage has raised a total of $11 million in equity financings to date from private investors.  NeuroPhage is based in Cambridge, MA.

 

Christine Brennan, Ph.D. Exec Director of Strategic Alliances and Head of Strategy and Operations, Novartis

Dr. Brennan joined Novartis Institutes of BioMedical Research, Inc. (NIBRI) in January 2006 as Director of Strategic Alliances and was responsible for all business development activities for the Infectious Disease Research Group.  Since Aug. 2008, she’s been Head of Strategy & Operations for Strategic Alliances responsible for business development for opportunities outside of current disease areas as well as goal/strategy setting for Strategic Alliances.  Prior to joining NIBRI, Dr. Brennan served as Director of Business Development at the biopharmaceutical company, EnVivo Pharmaceuticals, Inc., where she led the company’s business development initiatives and acted as alliance manager for the company’s collaborations.  Prior to EnVivo, she was Strategic Planning Analyst and then promoted to Product Manager for Cardizem LA (hypertension drug) at Biovail Corporation.  Prior to Biovail, Dr. Brennan was Scientific Analyst in the business development group at Cogent Neuroscience, Inc., a start-up biotechnology company. She received her Ph.D. in neuroscience from Dartmouth College in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Novartis Institutes of BioMedical Research, Inc.

Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz, two companies with a rich and diverse corporate history. Throughout the years, Novartis and its predecessor companies have discovered and developed many innovative products for patients and consumers worldwide. Their mission is to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. They also provide shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.

 

 

 

 

 

Mirza Cifric, Corporate Development, FORMA Therapeutics

Mirza Cifric is a life sciences entrepreneur currently heading Corporate Development function with FORMA Therapeutics Inc. in Cambridge, MA. Previously, Mirza was a co-founder and CEO of Solmap Pharmaceuticals (sold in 2009) a computer assisted drug design venture in Cambridge MA. He is a co-founder of ImThera Medical, a San Diego based neuro-prosthetic medical device company. In his early career he held various positions in the life sciences group at Mercury (NASDAQ:MRCY) concluding with a General Manager of Biomedical business. Mirza holds a BS in Electrical and Computer Engineering from Northeastern University and completed Executive Program at Harvard Business School.

FORMA Therapeutics Inc.

FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed.  FORMA is building on the scientific vision of its academic founders: Stuart Schreiber, Todd Golub and Mike Foley, all of the Broad Institute of Harvard and MIT.

FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing.

Leslie Williams, Co-Founder and CEO, Amplicea Therapeutics

Leslie was recognized in 2006 as one of the top 100 leaders in life sciences by PharmaVOICE magazine. Williams joined the specialty pharmaceutical company, Ventaira, in 2003 in the dual roles of VP of business and commercial development, and COO and became President and CEO in 2004.  Ventaira was sold in 2007. Prior to Ventaira, Williams was director of marketing for INO Therapeutics, Inc., where she played a significant role in the development of INOmax (nitric oxide), a drug for treating pulmonary hypertension. Among her many accomplishments she helped orchestrate the New Drug Application submission to the FDA for INOmax for inhalation.  Responsible for the commercial aspects of INOmax's U.S. market introduction, from setting objectives and strategy to developing key constituency groups and expert advisory boards, as well as representing INO Therapeutics on Capitol Hill, Williams also assisted with expansion of the INO-therapy platform into the European marketplace. (The company was acquired by Ikaria Holdings in 2007 for some $670 million.) Williams's experience also includes commercial positions at Merck and GlaxoSmithKline, and drug-delivery and monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.) where she also discovered, developed and managed “OptimizOR”, an efficiency and scheduling tool utilizing mathematical modeling.  Leslie was a Venture Partner with Battelle Ventures, serves on the Board of CDI Bioscience, a company that has developed an innovative technology for increasing the yield of bioproducts and also serves on the board of Hepregen, an MIT spin out, which has developed a stable and highly functional micro- liver model to be used for ADME/Toxicity testing and drug screening.  Leslie currently serves as Co-Founder, President & CEO for Amplicea Therapeutics, Inc, an early stage Cancer Therapeutics company in Cambridge, MA.  The Company’s mission is to exploit endogenous biological systems to improve and amplify tumor targeting.    Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree biology/nursing with honors from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa. Leslie left active patient care to seek and evaluate new technologies that impact health and the life sciences.

Amplicea Therapeutics, Inc.

Amplicea Therapeutics, Inc. is a privately-held emerging biotechnology company focused on the development of a transformational drug delivery platform technology that harnesses the body's own biological cascades to amplify the delivery of drugs to the diseased site, allowing drugs to more effectively and safely treat cancerous tumors and other diseases. Founded in 2009, Amplicea Therapeutics is based in Cambridge, MA

 

 

Have questions about Career Paths in Therapeutic Life Sciences Companies? Contact Propel Careers and MassDevice

When & Where


Cooley Godward Kronish LLP
500 Boylston Street
14th Floor
Boston, 02116

Wednesday, January 27, 2010 from 5:30 PM to 8:00 PM (EST)


  Add to my calendar

Organizer

Propel Careers and MassDevice

The mission of Propel Careers is to connect top talent with companies for full time, project based, and internship opportunities. Through these connections, we cultivate talent to produce the next generation of successful leaders.   

The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.

  Contact the Organizer

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.